الفهرس 
OSTEOARTHRITISOnly 14 pages are availabe for public view
 |  | from | 322 |  |  |
| | | from | 322 | | |
Abstract
SUMMARY
Osteoarthritis (OA) also known as degenerative arthritis or degenerative joint disease or osteoarthrosis, is a group of mechanical abnormalities involving degradation of joints including articular cartilage and subchondral bone. Symptoms may include joint pain, tenderness, stiffness, locking, and sometimes an effusion.
Because of their multi-potent capabilities, MSC lineages have been used successfully in animal models to regenerate articular cartilage and in human models to regenerate bone. The number of MSCs that can be isolated from bone marrow is fairly limited. As a result, most research in cartilage regeneration has focused on the use of culture expanded cells. This means that cells are isolated and then placed into various growth factors to be grown to higher numbers over a period of weeks in an ex-vivo monolayer culture.
This thesis was carried out to assess the therapeutic efficacy of the use of growth factors (stem cell factor) as mobilizing factors on stem cells in white mice in comparison to the effect of direct intra-articular mesenchymal stem cell transplantation on healing of osteoarthritic lesions of knee joint in white mice.
This study was performed on 100 adult male rats. OA was induced using insulin syringes for osteotomy in 80 rats bilaterally in both knee joints and 20 healthy adult male rats were left without induction of OA as normal healthy control group. Our clinical score of OA for the rats was assessed after 3 weeks from induction of OA (to ensure occurence of OA) and after 12 weeks from occurrence of OA and introduction of therapies (to show response to therapies with MSCs and SCF injections). Histopathological assessment was done and slides were stained with H and E, Toluidine blue, Masson’s trichrome stain and PAS to illustrate pathological changes to induced knee OA and assess response to UC-MSCs and SCF therapies by different routes.
MSCs in our study were obtained from human Umbilical cord blood (CB MSCs) and Wharton’s jelly of umbilical cord following Caesarian sections. MSCs were injected intraarticular after 2-4 weeks of in vitro culture on DMEM. Also, SCF was used to mobilize autologus MSCs towards knee with induced OA. SCF was injected by 2 routes: Intraarticular (IC) and Intravenous (IV).
The presence of autologus MSCs in rat’s blood, was confirmed by flowcytometry for CD34 surface marker. In-Vitro cultured UC-MSCs in presence of TGF-beta3 were assessed by immunohistochemistry for the presence of in-vitro acquired CD 44 surface marker.
Results:
SC WJ treated group showed best therapeutic response to cartilage cell grade, subchondral bone stage and grade. SC CB treated group show only good response to this therapy as regards cartilage stain grade only.
SCF IV treated group showed best therapeutic response to therapy as regards cartilage cell grade and synovium vascular grade. SCF IC treated group responded well to cartilage stage only.
Discussion:
Improvement to OA with different therapies (MSCs and SCF therapies) occurred in all treated groups with best therapeutic response to therapy in SC WJ treated group followed by SCF IV treated group.